Prognostic Factors of Patients With ADHF

Acute Decompensated Heart Failure Clinical Trial

Official title:

Elevated Blood Monocyte Count Predicts 1 Year Poor Outcomes for Patients Admitted With Acute Decompensated Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04390919
• Other study ID #: 2020-05-04
• Status: Completed
• Start date: August 2, 2011
• Est. completion date: February 16, 2015

Study information

• Verified date: May 2020
• Source: Chongqing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To explore the prognostic indicators for patients with ADHF

Description:

According to ESC Guidelines for the diagnosis of acute heart failure 2008, patients with ADHF were diagnosed, and their medical history, laboratory examination and treatment plan were retrospectively analyzed, and the patients were followed up for 1 year. The 1-year outcomes of patients were analyzed to explore the prognostic indicators for patients with ADHF

Recruitment information / eligibility

• Status: Completed
• Enrollment: 362
• Est. completion date: February 16, 2015
• Est. primary completion date: February 16, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 94 Years

Eligibility

Inclusion Criteria:

• Patients with ADHF diagnosed according to ESC Guidelines for the diagnosis of acute heart failure 2008

Exclusion Criteria:

• disorders of the hematopoietic system, history of cancer and/or previous treatment with chemotherapy, the infection caused by various pathogens, chronic inflammatory conditions, glucocorticoid therapy and/or histories of glucocorticoid use 3 months before the admission and acute myocardial infarction or coronary revascularization within the past 6 months. Also, patients who did not have a differential WBC count or who were lost to follow-up were excluded.

Related Conditions & MeSH terms

• Acute Decompensated Heart Failure
• Heart Failure

Intervention

Other:
• elevated monocyte count
The monocyte count at admission was higher than 0.445×10*9 cells/L

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chongqing Medical University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause death	The primary end point was one-year all-cause death	1 year
Secondary	HF-related rehospitalization	the secondary end point was one-year HF-related rehospitalization.	1 year